Previous 10 | Next 10 |
2023-12-29 14:12:19 ET Summary The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have ...
2023-12-19 22:37:01 ET Summary John Paulson's 13F portfolio value increased by 9% to $1.12 billion this quarter. The top five positions in the portfolio were Horizon Therapeutics, Bausch Health, Brightsphere Investment Group, NovaGold, and Perpetua Resources. Paulson's stake i...
2023-12-18 00:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-07 08:45:00 ET Shares of relatively small biotech companies often soar when they get positive news from regulators, and that's exactly what Madrigal Pharmaceuticals (NASDAQ: MDGL) and Bluebird Bio (NASDAQ: BLUE) are awaiting. Both companies expect to land major appro...
2023-12-06 18:59:01 ET Summary 89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMM...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-11-30 05:50:00 ET You've probably heard the old adage, "It takes money to make money." And it's true. You do have to have some initial money to invest. But you don't necessarily have to have a lot of up-front cash -- especially if you pick the right stocks. Got $2,000? Here are thr...
2023-11-22 09:33:29 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024 Madrigal adds former Sanofi executive as commercial chief Seeking Alpha’s Quant Rating on Madrigal Pharmaceuticals Fo...
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. ...
2023-11-15 10:12:31 ET More on Madrigal, Newmont, etc. Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024 Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024 Newmont: Margins Improve, But Production Belo...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...